Wave Life Sciences (WVE) Projected to Post Earnings on Thursday

Wave Life Sciences (NASDAQ:WVE) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to post earnings of ($0.26) per share and revenue of $11.65 million for the quarter.

Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to analysts’ expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. On average, analysts expect Wave Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Wave Life Sciences Trading Down 17.1 %

Shares of Wave Life Sciences stock opened at $6.41 on Wednesday. Wave Life Sciences has a twelve month low of $4.25 and a twelve month high of $16.74. The firm’s 50-day moving average price is $8.02 and its 200 day moving average price is $11.33. The firm has a market capitalization of $987.72 million, a PE ratio of -5.77 and a beta of -0.91.

Insider Buying and Selling at Wave Life Sciences

In other news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the sale, the director now directly owns 16,115 shares of the company’s stock, valued at approximately $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. The trade was a 33.31 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 29.10% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Wedbush started coverage on shares of Wave Life Sciences in a report on Tuesday, April 8th. They set an “outperform” rating and a $18.00 target price for the company. Jefferies Financial Group initiated coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Finally, Cantor Fitzgerald began coverage on Wave Life Sciences in a report on Tuesday, April 29th. They set an “overweight” rating and a $10.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Wave Life Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $21.17.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.